New drug combo aims to extend remission in ovarian cancer
NCT ID NCT07225270
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, bevacizumab alone, or monitoring only. The study measures how long the cancer stays under control and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rinatabart sesutecan (Rina-S) and bevacizumab
What this could lead to
If successful, this could offer a new maintenance option to help keep platinum-sensitive ovarian cancer from returning after chemotherapy.
What could go wrong
This is an early-stage Phase 3 trial, so results are not yet proven. Side effects from Rina-S or bevacizumab may occur, and the combination may not improve outcomes over standard care alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hyogo Cancer Center
RECRUITINGAkashi, Hyōgo, Japan
-
Miami Valley Hospital South
RECRUITINGCenterville, Ohio, 45459, United States
-
Mie University Graduate School Of Medicine
RECRUITINGTsu, Mie-ken, Japan
-
Mt. Sinai Comprehensive Cancer Center
RECRUITINGMiami, Florida, 33140, United States
-
National Hospital Organization Hokkaido Cancer Center
RECRUITINGSapporo, Hokkaido, Japan
-
Niigata University Medical & Dental Hospital
RECRUITINGNiigata, Japan
-
Okayama University Hospital
RECRUITINGOkayama, Japan
-
Osaka Medical and Pharmaceutical University Hospital
RECRUITINGTakatsuki, Osaka, Japan
-
Saitama Medical University International Medical Center
RECRUITINGHidaka, Saitama, Japan
-
Sapporo Medical University Hospital
RECRUITINGSapporo, Hokkaido, Japan
-
Sarasota Memorial Health Care System
RECRUITINGSarasota, Florida, 34239, United States
-
The Cancer Institute Hospital of JFCR
RECRUITINGTokyo, Japan
-
Zangmeister Cancer Center
RECRUITINGColumbus, Ohio, 43219, United States